Overview

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2023-05-31

Target enrollment:

Participant gender:

Summary

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Treatments:

Curcumin
Piperine